Physician profile
Lan C Tu
NPI 1184735334
$6,892.59
in general payments reported to CMS, 2019-2025
24 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $820 · 2021: $893 · 2022: $869 · 2023: $617 · 2024: $960 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.07 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,835.40 | 2019-2025 | Tezspire, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.54 | 2019-2025 | Jardiance |
| Amgen INC. | $625.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $547.28 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Gilead Sciences, INC. | $537.33 | 2019-2024 | |
| Novo Nordisk INC | $457.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $413.72 | 2019-2025 | |
| Glaxosmithkline, LLC. | $237.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $225.16 | 2019-2021 | |
| Genzyme Corporation | $212.05 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $204.23 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $186.47 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $137.34 | 2025 | Zoryve |
| Amarin Pharma, INC. | $134.45 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $119.78 | 2019-2024 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $74.60 | 2025 | The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $57.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $46.57 | 2025 | |
| Hologic Sales and Service, LLC | $22.78 | 2019 | |
| Biocryst US Sales Co., LLC | $21.84 | 2022 | |
| Ibsa Pharma INC. | $21.23 | 2021 | |
| Allergan, INC. | $16.94 | 2019 | |
| Insightec,INC | $16.56 | 2025 | Exablate |
| Teva Pharmaceuticals USA, INC. | $16.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.